VTYX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Given the investor's long-term strategy and beginner level, Ventyx Biosciences (VTYX) is not a good buy at this time. The stock is being acquired by Eli Lilly for $14 per share, which caps its upside potential. Analysts have downgraded the stock to Neutral with a price target of $14, aligning with the acquisition price. Additionally, the company's financial performance is weak, with declining net income and EPS. While hedge funds are increasing their positions, the limited growth potential due to the acquisition makes this stock unsuitable for long-term investment.
The technical indicators are mixed. The MACD is negative and contracting, suggesting bearish momentum. RSI is neutral at 62.67, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its pivot point of $13.938, with resistance levels at $13.972 and $13.994, and support levels at $13.904 and $13.882.
Hedge funds have increased their buying activity by 427.27% over the last quarter. Eli Lilly's acquisition of Ventyx Biosciences provides a guaranteed exit at $14 per share, minimizing downside risk.
The acquisition by Eli Lilly caps the stock's upside potential at $14 per share. Analysts have downgraded the stock to Neutral, and the company's financial performance shows declining net income and EPS. There is no recent congress trading data or significant insider activity.
In Q3 2025, revenue remained flat at $0, net income dropped by 35.24% YoY to -$22.83M, and EPS fell by 36% YoY to -$0.32. Gross margin also remained at 0%.
Analysts have downgraded the stock to Neutral due to the acquisition by Eli Lilly. Price targets have been reduced to $14, aligning with the acquisition price. This indicates limited growth potential for the stock.
